摘要
Background<br/>Current research that combines radiation with targeted therapy may dramatically improve prognosis of pancreatic ductal adenocarcinoma (PDAC). We investigated preclinical outcomes of DNA repair inhibitor targeted therapy associated with radiotherapy.<br/>Methods<br/>We searched Pubmed database to identify publications assessing DNA damage targeted therapies in preclinical models of PDACin vitro and in vivo. Standard enhancement ratio, median survival and growth delay were extracted.<br/>Results<br/>We identified fourteen publications using DNA repair targeted therapies in preclinical models of PDAC. Ten publications comprising twenty-eight experiments evaluated radiosensitization with different DNA repair inhibitors in vitro and displayed cell killing by a factor of 1.35 ± 0.047. Moreover, 86% (24/28) of in vitro experiments showed radiosensitization with DNA damage response inhibitor. However, only 60% (9/15) of the in vivo experiments presented radiosensitization effects.<br/>Conclusion<br/>DNA repair targeted therapies use promising radiosensitizers for PDAC and could successfully be translated into clinical trials.
学科与关键词
- DNA damage response and repair in pancreatic cancer development and therapyFarnood Parnia Rahnamay; Pazhooh Romina Danesh; Asemi Zatollah; Yousefi BahmanDNA Repair, 2021, prepublish.
- Radiosensitising Cancer Using Phosphatidylinositol-3-Kinase (PI3K), Protein Kinase B (AKT) or Mammalian Target of Rapamycin (mTOR) InhibitorsKasun, Wanigasooriya; Robert, Tyler; Joao D., Barros-Silva; Yashashwi, Sinha; Tariq, Ismail; Andrew D., BeggsCancers, 2020, 12(5): 1278.被引 7
- Pristimerin synergizes with gemcitabine through abrogating Chk1/53BP1-mediated DNA repair in pancreatic cancer cellsJiang Zhuangzhuang; Zhao Yang; Zhao Yang; Liu Yanqing; Tao LiFood and Chemical Toxicology, 2021, 147.
